Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Adlai Nortye Ltd. (ANL)

$12.50 -5.45% NASDAQ: ANL · 15-min delayed
  • NORTH BRUNSWICK, New Jersey
  • Public · NASDAQ: ANL
  • 109 employees
$640.8MMarket cap
109Employees
ANLNASDAQ
2023IPO

About Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Market cap
$640.8M
NASDAQ: ANL
$12.50 -5.45%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.88 $16.60

52-week range

Market cap
$640.8M
Dividend yield
8.0%
Shares outstanding
51.3M
Open
Day range
Prev close
Volume
IPO date
Sep 29, 2023

Adlai Nortye Ltd. (ANL) Stock Price

  • Trading 25% below its 52-week high.
  • Pays a dividend yielding about 8.0% annually.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Adlai Nortye Ltd..

Write a review
Newsroom

News about Adlai Nortye Ltd.

News & sentiment via Polygon.io

FAQ

Adlai Nortye Ltd.: frequently asked questions

Is Adlai Nortye Ltd. an American company?

Adlai Nortye Ltd. is a US-based company headquartered in North Brunswick, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Adlai Nortye Ltd. headquartered?

Adlai Nortye Ltd. is headquartered in North Brunswick, New Jersey, United States.

Is Adlai Nortye Ltd. publicly traded?

Yes — Adlai Nortye Ltd. is a publicly traded company. Its stock trades under the ticker symbol ANL on the NASDAQ.

What does Adlai Nortye Ltd. do?

Adlai Nortye Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →